Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

[News]

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

More... (http://www.news-medical.net/news/20131002/Data-analyses-from-Brisdelle-Phase-3-pivotal-trials-to-be-showcased-at-NAMS-meeting.aspx)